Alcon’s Cipro HC Otic Product Website Draws FDA Warning Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA objects to website claims that Cipro HC Otic is superior to Cortisporin. Alcon’s site also fails to reveal important risk information about the ear drops product, the agency’s ad review division says.
You may also be interested in...
Alcon Gets Third FDA Warning On Sales Claims For Eye And Ear Drugs
Nevanac joins Cipro HC Otic and Travaton in being cited by the agency’s advertising division.
India Highlights "Public Interest" To Reign In Prices For Non-Scheduled Drugs
Dr. Reddy's, GSK, Ranbaxy and UCB among manufacturers that could see prices reduced under government order that reflects issues raised in Gleevec patent dispute.